From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology* / Q000209:etiology*; D004359:Drug Therapy, Combination; D006801:Humans; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000009:adverse effects* / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D014481:United States / Q000453:epidemiology
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin